In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in ALL

Poster Session #5

Jointly provided by Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Program Overview

 

Abstracts Discussed

Current first-line treatment of acute lymphoblastic leukemia (ALL) comprises induction, consolidation, intensification, and maintenance chemotherapy. Asparaginase is a critical component during induction, consolidation and intensification in pediatric and adult/young adult populations leading to improvements in event-free and overall survival. Yet the toxicity profile of asparaginase and drug-shortages both contribute to insufficient exposure to asparaginase and suboptimal outcomes in ALL. Appropriate management of patients with ALL is challenging, particularly for adult-focused HCPs unfamiliar with pediatric and adolescent and young adults (AYA) protocols.

In order to address these educational needs, this CME-certified activity will focus on key studies presented at ASH 2021; including results from the Graaph-2014 (studied the omission of HD-AraC during consolidation of Ph-positive ALL patients treated with nilotinib and low-intensity chemotherapy) and the UKALL14 (assessment of addition of nelarabine to standard chemotherapy in T-cell ALL) trials.

Faculty

Lori Muffly, MD, MS
Associate Professor of Medicine
Division of Blood and Marrow Transplantation & Cellular Therapy
Stanford University
Stanford, CA

Marlise Luskin, MD, MSCE
Assistant Professor of Medicine
Harvard Medical School
Division of Leukemia
Dana-Farber Cancer Institute
Boston, MA

Target Audience

This education activity has been designed to meet the needs of:

  • Hematologists, medical oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other HCPs interested in the treatment of patients with ALL

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Review recently presented clinical trial data in adults with treatment naïve Philadelphia chromosome positive acute lymphoblastic leukemia 

  • Review recently presented clinical trial data in adults with treatment naïve T-cell acute lymphoblastic leukemia

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period of June 15, 2022 through June 15, 2023, participants must:

  • Read the learning objectives and faculty disclosures

  • Complete the pretest

  • Study the educational activity

  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon successful completion (75% passing score) and receipt of the activity posttest and evaluation form. Certificates will be sent via email within four weeks of receipt of a completed evaluation form.

Accreditation

Physician Continuing Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Bonum Continuing Education LLC.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this Other activity (multi-channel video and discussion) for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

 

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

 
  • Lori Muffly, MD, MS
    Consulting: Amgen, Astellas, CTI Biopharma, Kite, Medexus, Pfizer
    Contracted Research: Adaptive Biotechnologies, Astellas, Bristol Myers Squibb, Jasper Therapeutics, Kite
    Speaker’s Bureau: Adaptive Biotechnologies

    Marlise Luskin, MD, MSCE
    Advisory Board: Pfizer
    Contracted Research: AbbVie, Novartis

  • Bonum Continuing Education LLC staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

    The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Minimum System Requirements

Media: Internet
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)

Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

Plug-in: Adobe® Flash® Player 10

• Adobe® Flash® Player 10 plug-in should be downloaded

• Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

Privacy Policy

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

Contact Information

For information about ACCME certification of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

Release date: June 15, 2022
Expiration date: June 15, 2023
Estimated time to complete activity: 30 minutes